Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease
Conditions
Diabetic Nephropathies · Kidney Failure, Chronic · Diabetes Mellitus Type 1 · Heart Failure
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Stanford University Medical Center, Stanford, California, United States
Contact: Principal Investigator (Marina Basina, MD)David Maahs, MD (Sub-investigator)Barbara Davis Center / University of Colorado Denver, Aurora, Colorado, United States
Contact: Principal Investigator (Sarit Polsky, MD)Halis Akturk, MD (Sub-investigator)AdventHealth, Orlando, Florida, United States
Contact: Principal Investigator (Tina Thethi)Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
Contact: Principal Investigator (Amisha Wallia, MD)Joslin Diabetes Center, Boston, Massachusetts, United States
Contact: Study coordinator (Christine Mendonca) · christine.mendonca@joslin.harvard.edu · 617-334-2257Contact: Principal Investigator (Alessandro Doria, MD PhD MPH)Elena Toschi, MD (Sub-investigator)Sylvia Rosas, MD (Sub-investigator)Washington University, St Louis, Missouri, United States
Contact: Principal Investigator (Janet McGill, MD)Kai Jones, MD (Sub-investigator)Maamoun Salam, MD (Sub-investigator)Huda Al-Bahadili, MD (Sub-investigator)SUNY Upstate Medical University, Syracuse, New York, United States
Contact: Principal Investigator (Ruth Weinstock, MD)Malek El Muayed, MD, MSCI (Sub-investigator)Katherine McPhee, MSN, FNP-C, RN (Sub-investigator)Albert Einstein College of Medicine / Montefiore Medical Center, The Bronx, New York, United States
Contact: Principal Investigator (Matthew Abramowitz, MD)Jill Crandall, MD (Sub-investigator)Justin Mathew, MD (Sub-investigator)Cleveland Clinic Foundation, Cleveland, Ohio, United States
Contact: Principal Investigator (Luiza Caramori, MD PhD)Keren Zhou, MD (Sub-investigator)Oregon Health and Science University, Portland, Oregon, United States
Contact: Principal Investigator (Rodica Busui, MD, PhD)Andrew Ahmann, MD (Sub-investigator)University of Texas Southwestern, Dallas, Texas, United States
Contact: Principal Investigator (Ildiko Lingvay, MD)Amy Shah, MD (Sub-investigator)Oksana Hamidi, DO (Sub-investigator)University of Washington, Seattle, Washington, United States
Contact: Principal Investigator (Petter Bjornstad, MD)Irl Hirsch, MD (Sub-investigator)Ian de Boer, MD (Sub-investigator)Kalie Tommerdahl, MD (Sub-investigator)Providence Sacred Heart Medical Center, Spokane, Washington, United States
Contact: Principal Investigator (Katherine R. Tuttle, MD)Radica Alicic, MD (Sub-investigator)Michael Ryan, MD (Sub-investigator)Unversity of Calgary, Calgary, Alberta, Canada
Contact: Principal Investigator (Ronald Sigal, MD MPH)Alberta Diabetes Institute, Edmonton, Alberta, Canada
Contact: Principal Investigator (Peter Senior, MD)Anna Lam, MD (Sub-investigator)St. Paul's Hospital, Vancouver, British Columbia, Canada
Contact: Principal Investigator (Adeera Levin, MD)Sean Barbour, MD (Sub-investigator)LMC Diabetes and Endocrinology, Toronto, Ontario, Canada
Contact: Principal Investigator (Ronnie Aronson, MD)Toronto General Hospital, Toronto, Ontario, Canada
Contact: Principal Investigator (David Cherney, MD)Bruce Perkins, MD MPH (Sub-investigator)Vikas S. Sridhar, MD (Sub-investigator)Ayodele Odutayo, MD (Sub-investigator)Huajing Ni, MD (Sub-investigator)Taewon Yi, MD (Sub-investigator)Institut de Recherches Cliniques de Montréal, Montreal, Quebec, Canada
Contact: Principal Investigator (Remi Rabasa-Lhoret, MD)Nadine Taleb, MD (Sub-investigator)
Study leads
Alessandro Doria, MD PhD MPH
Principal Investigator
Joslin Diabetes Center
Michael Mauer, MD
Principal Investigator
University of Minnesota
David Cherney, MD PhD
Principal Investigator
University of Toronto